Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 7/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15984703 | 0.87 | CTSL (0.44) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL106104 | 0.81 | ALDH1A1 (0.39) | ALOX15ALDH1A1 | |
| SCHEMBL17503456 | 0.77 | RXRA (0.64) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL24076449 | 0.76 | CA1 (0.52) | TSHRCA1CA2CA12CA7 | |
| SCHEMBL24214190 | 0.76 | TSHR (0.44) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL17869355 | 0.76 | TSHR (0.55) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL9471910 | 0.74 | RXRA (0.56) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL15956227 | 0.74 | TP53 (0.52) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL668472 | 0.74 | TSHR (0.52) | TSHRTP53SRD5A2CA1CA2 | |
| SCHEMBL5084654 | 0.73 | TSHR (0.57) | TSHRTP53SRD5A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
| US-9233111-B2 | Pyrrolo pyrimidine derivatives | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| EP-2729466-B1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| EP-2205564-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| EP-2729466-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| EP-2426109-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013008095-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| CN-101835755-A | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| EP-1984340-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | TSHR 4236/4885TP53 1670/4885SRD5A2 651/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | TSHR 1229/4885TP53 1892/4885SRD5A2 3617/4885 |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | TSHR 3187/4885TP53 3655/4885SRD5A2 2444/4885 |
| US-20140243306-A1 | NOVEL PYRROLO PYRIMIDINE DERIVATIVES | BTK, LCK, ZAP70 | TSHR 3222/4885TP53 430/4885SRD5A2 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.